Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

NCT05043987 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped New IND sponsor to initiate a separate study

Conditions

Pancreatic Cancer
Gastric Cancer

Interventions

DRUG: CPO102

Sponsor

Conjupro Biotherapeutics, Inc.

Collaborators

[object Object]